Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesise that pre-application of Qutenza® patches to the skin may reduce
pain at the site of Remodulin® SC infusion (sited 1 to 2 weeks later at the site of Qutenza
pre-application), in which case it would greatly improve the quality of life of the patients,
and enable many more to continue with this treatment. It may also provide new information to
support the use of Qutenza® patches for preventing and reducing pain produced by
inflammation.
The present study will explore the efficacy of single applications of Qutenza® (capsaicin 8%
patch) in reducing site pain caused by continuous SC infusion of Remodulin®, in pulmonary
arterial hypertension patients, as assessed by changes in subjective pain rating score and/or
pain and sensory testing.